Growth Metrics

Eli Lilly (LLY) Retained Earnings (2016 - 2026)

Eli Lilly filings provide 18 years of Retained Earnings readings, the most recent being $29.5 billion for Q1 2026.

  • On a quarterly basis, Retained Earnings rose 881.91% to $29.5 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $29.5 billion, a 881.91% increase, with the full-year FY2025 number at -$2.9 billion, up 33.36% from a year prior.
  • Retained Earnings hit $29.5 billion in Q1 2026 for Eli Lilly, up from -$2.9 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $29.5 billion in Q1 2026 to a low of -$4.4 billion in Q2 2024.
  • Median Retained Earnings over the past 5 years was -$3.8 billion (2025), compared with a mean of $2.5 billion.
  • Biggest five-year swings in Retained Earnings: crashed 144.28% in 2023 and later soared 881.91% in 2026.
  • Eli Lilly's Retained Earnings stood at $10.0 billion in 2022, then plummeted by 143.09% to -$4.3 billion in 2023, then grew by 0.12% to -$4.3 billion in 2024, then skyrocketed by 33.36% to -$2.9 billion in 2025, then skyrocketed by 1124.79% to $29.5 billion in 2026.
  • The last three reported values for Retained Earnings were $29.5 billion (Q1 2026), -$2.9 billion (Q4 2025), and -$3.2 billion (Q3 2025) per Business Quant data.